The biology behind interleukin-6 targeted interventions

Current Opinion in Rheumatology

Volumn 28, Issue 2, 2016, Pages 152-160

  Liu, Xiao ^a   Jones, Gareth W ^a   Choy, Ernest H ^a   Jones, Simon A ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

biologics; cytokines; glycoprotein 130; interleukin 6; therapy

Indexed keywords

GLYCOPROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; TOCILIZUMAB; GLYCOPROTEIN GP 130; IL6 PROTEIN, HUMAN; IL6ST PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ACUTE PHASE RESPONSE; ADAPTIVE IMMUNITY; BIOLOGICAL ACTIVITY; CD4+ T LYMPHOCYTE; CLINICAL PRACTICE; HOMEOSTASIS; HUMAN; IMMUNOBIOLOGY; INNATE IMMUNITY; PRIORITY JOURNAL; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION; TH17 CELL; TH2 CELL; TH22 CELL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTIBODIES, MONOCLONAL, HUMANIZED; CYTOKINE RECEPTOR GP130; HUMANS; INTERLEUKIN-6; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84957440448     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000255     Document Type: Review

References (100)

1. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 2015; 27:127-133.
2. Sivera F, Wechalekar MD, Andres M, et al. Interleukin-1 inhibitors for acute gout. Cochrane Database Syst Rev 2014; 9:CD009993.
3. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61:1693-1700.
4. Melton L, Coombs A. Actemra poised to launch IL-6 inhibitors. Nat Biotechnol 2008; 26:957-959.
5. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16:448-457.
6. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265:621-636.
7. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994; 368:339-342.
8. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-238.
9. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 1986; 324:73-76.
10. Liu F, Poursine-Laurent J, Wu HY, Link DC. Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation. Blood 1997; 90:2583-2590.
11. Cressman DE, Greenbaum LE, DeAngelis RA, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996; 274:1379-1383.
12. Murray C, Griffin EW, O'Loughlin E, et al. Interdependent and independent roles of type I interferons and IL-6 in innate immune, neuroinflammatory and sickness behaviour responses to systemic poly I:C. Brain Behav Immun 2015; 48:274-286.
13. Stoian I, Manolescu B, Atanasiu V, et al. IL-6-STAT-3-hepcidin: linking inflammation to the iron metabolism. Rom J Intern Med 2007; 45:305-309.
14. Kraakman MJ, Kammoun HL, Allen TL, et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab 2015; 21:403-416.
15. Taniguchi K, Wu LW, Grivennikov SI, et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 2015; 519:57-62.
16. Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol 2013; 9:154-163.
17. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011; 121:3375-3383.
18. Wong PK, Quinn JM, Sims NA, et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 2006; 54:158-168.
19. Ohshima S, Saeki Y, Mima T, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A 1998; 95:8222-8226.
20. Nowell MA, Richards PJ, Horiuchi S, et al. Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 2003; 171:3202-3209.
21. Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998; 187:461-468.
22. Eugster HP, Frei K, Kopf M, et al. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 1998; 28:2178-2187.
23. Haruta H, Ohguro N, Fujimoto M, et al. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011; 52:3264-3271.
24. Screpanti I, Musiani P, Bellavia D, et al. Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice. J Exp Med 1996; 184:1561-1566.
25. Lattanzio G, Libert C, Aquilina M, et al. Defective development of pristane-oilinduced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol 1997; 151:689-696.
26. McLoughlin RM, Witowski J, Robson RL, et al. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest 2003; 112:598-607.
27. McLoughlin RM, Hurst SM, Nowell MA, et al. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J Immunol 2004; 172:5676-5683.
28. Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63:1149-1157.
29. Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989; 58:573-581.
30. Yamasaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 1988; 241:825-828.
31. Yoshida K, Taga T, Saito M, et al. Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A 1996; 93:407-411.
32. Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374:1-20.
33. Ernst M, Jenkins BJ. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 2004; 20:23-32.
34. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41-51.
35. O'Shea JJ, Laurence A, McInnes IB. Back to the future: Oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol 2013; 9:173-182.
36. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22:347-352.
37. Schroers A, Hecht O, Kallen KJ, et al. Dynamics of the gp130 cytokine complex: A model for assembly on the cellular membrane. Protein Sci 2005; 14:783-790.
38. Honda M, Yamamoto S, Cheng M, et al. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol 1992; 148:2175-2180.
39. Novick D, Engelmann H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med 1989; 170:1409-1414.
40. Baran P, Nitz R, Grotzinger J, et al. Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling. J Biol Chem 2013; 288:14756-14768.
41. Jones SA. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 2005; 175:3463-3468.
42. Jones SA, Horiuchi S, Topley N, et al. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001; 15:43-58.
43. Peters M, Jacobs S, Ehlers M, et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 1996; 183:1399-1406.
44. Gearing DP, Cosman D. Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor. Cell 1991; 66:9-10.
45. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012; 8:1237-1247.
46. Jostock T, Mullberg J, Ozbek S, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001; 268:160-167.
47. Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993; 82:1120-1126.
48. Nowell MA, Williams AS, Carty SA, et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol 2009; 182:613-622.
49. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000; 6:583-588.
50. Lacroix M, Rousseau F, Guilhot F, et al. Novel Insights into Interleukin 6 (IL-6) Cis-and Trans-signaling Pathways by Differentially Manipulating the Assembly of the IL-6 Signaling Complex. J Biol Chem 2015; 290:26943-26953.
51. Lissilaa R, Buatois V, Magistrelli G, et al. Although IL-6 trans-signaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. J Immunol 2010; 185:5512-5521.
52. Ishibashi T, Kimura H, Uchida T, et al. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci U S A 1989; 86:5953-5957.
53. Davies R, Choy E. Clinical experience of IL-6 blockade in rheumatic diseases: implications on IL-6 biology and disease pathogenesis. Semin Immunol 2014; 26:97-104.
54. Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014; 10:720-727.
55. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101:311-320.
56. Hurst SM, Wilkinson TS, McLoughlin RM, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14:705-714.
57. Fielding CA, McLoughlin RM, McLeod L, et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol 2008; 181:2189-2195.
58. Rabe B, Chalaris A, May U, et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008; 111:1021-1028.
59. Chalaris A, Rabe B, Paliga K, et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007; 110:1748-1755.
60. McLoughlin RM, Jenkins BJ, Grail D, et al. IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 2005; 102:9589-9594.
61. Chen Q, Wang WC, Bruce R, et al. Central role of IL-6 receptor signaltransducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stress. Immunity 2004; 20:59-70.
62. Kimura A, Kishimoto T. Th17 cells in inflammation. Int Immunopharmacol 2011; 11:319-322.
63. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40:1830-1835.
64. Samson M, Audia S, Janikashvili N, et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64:2499-2503.
65. Matthews VB, Allen TL, Risis S, et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 2010; 53:2431-2441.
66. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on musclederived interleukin-6. Physiol Rev 2008; 88:1379-1406.
67. Wunderlich FT, Strohle P, Konner AC, et al. Interleukin-6 signaling in liverparenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab 2010; 12:237-249.
68. Peters M, Schirmacher P, Goldschmitt J, et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med 1997; 185:755-766.
69. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and antiinflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813:878-888.
70. Keller P, Keller C, Carey AL, et al. Interleukin-6 production by contracting human skeletal muscle: Autocrine regulation by IL-6. Biochem Biophys Res Commun 2003; 310:550-554.
71. Penkowa M, Keller C, Keller P, et al. Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise. FASEB J 2003; 17:2166-2168.
72. van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 2003; 88:3005-3010.
73. Carey AL, Steinberg GR, Macaulay SL, et al. Interleukin-6 increases insulinstimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 2006; 55:2688-2697.
74. Poli V, Balena R, Fattori E, et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J 1994; 13:1189-1196.
75. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A 1993; 90:11924-11928.
76. Fulciniti M, Hideshima T, Vermot-Desroches C, et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009; 15:7144-7152.
77. Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 2008; 57:684-694.
78. Murphy PG, Ramer MS, Borthwick L, et al. Endogenous interleukin-6 contributes to hypersensitivity to cutaneous stimuli and changes in neuropeptides associated with chronic nerve constriction in mice. Eur J Neurosci 1999; 11:2243-2253.
79. Braun O, Dewitz C, Moller-Hackbarth K, et al. Effects of blockade of peripheral interleukin-6 trans-signaling on hippocampus-dependent and independent memory in mice. J Interferon Cytokine Res 2013; 33:254-260.
80. Klein B, Wijdenes J, Zhang XG, et al. Murine antiinterleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78:1198-1204.
81. Klein B, Lu ZY, Gaillard JP, et al. Inhibiting IL-6 in human multiple myeloma. Curr Top Microbiol Immunol 1992; 182:237-244.
82. Lu ZY, Brochier J, Wijdenes J, et al. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy: towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol 1992; 22:2819-2824.
83. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112:3959-3964.
84. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the longterm efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601-608.
85. Chirino AJ, Ary ML, Marshall SA. Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 2004; 9:82-90.
86. Boulianne GL, Hozumi N, Shulman MJ. Production of functional chimaeric mouse/human antibody. Nature 1984; 312:643-646.
87. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A 1984; 81:6851-6855.
88. Vincke C, Muyldermans S. Introduction to heavy chain antibodies and derived Nanobodies. Methods Mol Biol 2012; 911:15-26.
89. Silverman J, Liu Q, Bakker A, et al. Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 2005; 23:1556-1561.
90. Schett G, Elewaut D, McInnes IB, et al. How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med 2013; 19:822-824.
91. Tanaka Y, Martin Mola E. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis 2014; 73:1595-1597.
92. Waage A, Kaufmann C, Espevik T, Husby G. Interleukin-6 in synovial fluid from patients with arthritis. Clin Immunol Immunopathol 1989; 50:394-398.
93. Padberg F, Feneberg W, Schmidt S, et al. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. J Neuroimmunol 1999; 99:218-223.
94. Schuett H, Oestreich R, Waetzig GH, et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2012; 32:281-290.
95. Tsantikos E, Maxwell MJ, Putoczki T, et al. Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice. Arthritis Rheum 2013; 65:2691-2702.
96. Richards PJ, Nowell MA, Horiuchi S, et al. Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum 2006; 54:1662-1672.
97. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004; 21:491-501.
98. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010; 138:2101-2114.
99. Matsumoto S, Hara T, Mitsuyama K, et al. Essential roles of IL-6 transsignaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitisassociated premalignant cancer in a murine model. J Immunol 2010; 184:1543-1551
100. Sodenkamp J, Waetzig GH, Scheller J, et al. Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. Immunobiology 2012; 217:996-1004.